Please login to the form below

Not currently logged in
Email:
Password:

Tourette's syndrome

This page shows the latest Tourette's syndrome news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

The acquisition of Abide added a drug for Tourette’s syndrome and neuropathic pain called ABX 1431 – re-christened Lu AG06466 – and there has been some bad news on that front ... too. At the end of last week, Lundbeck said the monoacylglycerol

Latest news

  • Teva’s weak pipeline hit by Tourette’s drug trial failure Teva’s weak pipeline hit by Tourettes drug trial failure

    Drug wasn't able to improve on placebo. Teva’s effort to reinvigorate its business with new product launches has suffered a setback after a drug for Tourette’s syndrome failed ... It’s not the first drug in the VMAT2 inhibitor class to miss the

  • Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

    up. The acquisition of Alder comes after Lundbeck bought  Abide Therapeutics for $400m earlier this year – adding mid-stage drug candidate ABX-1431 for Tourette’s syndrome – and last year’s ... $1b purchase of  Prexton Therapeutics and phase 2

  • Lundbeck snaps up Abide Therapeutics for $400m Lundbeck snaps up Abide Therapeutics for $400m

    Also acquires its lead drug for Tourette’s syndrome. Danish drugmaker Lundbeck has moved to bolster its pipeline with a $400m deal to acquire Abide Therapeutics and its lead drug for ... ABX 1431 is in a phase 2a trial in Tourette’s syndrome –

  • Neurocrine bags FDA approval for first tardive dyskinesia drug Neurocrine bags FDA approval for first tardive dyskinesia drug

    Neurocrine says it is also expecting to report results for a trial of valbenazine in children with Tourette's syndrome next month, although an earlier study in adults failed to show ... If positive, Neurocrine is hoping to start a phase III trial in

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma in 2015. ... Both companies are also exploring the use of their respective drugs to prevent tics associated with Tourette's syndrome.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics